Clinical Trials

The purpose of this study is the evaluation of morphology of capillaries in nailfolds of healthy children and children with the diagnosis of systemic auto-immune/inflammatory diseases.

The purpose of this study is to identify biomarkers in people with autoimmune or inflammatory disease and in healthy people. We will use these biomarkers to develop tests that will help us better understand the same biomarkers in the blood of people who have autoimmune and inflammatory diseases.

This study is being done to learn more about diseases with chronic and harmful inflammation. This study will look at what causes these diseases;  whether these diseases are inherited (genetic) or acquired (not genetic or inherited); and what are the signs, symptoms, or tests that can be used to predict how a patient will respond to therapy or which therapy may be the best one to use.

The purpose of the study is to learn more about autoimmunity and potential mother to baby transmission of pathogenic antibodies. The collected research samples from children will be frozen and stored at the Mayo Clinic and will be used for future studies of autoimmune diseases.

The purpose of this study is to evaluate the long-term and repeated use safety and effectiveness of caplacizumab in patients who completed previous study ALX0681-C301.

The purpose of this study is to establish a repository consisting of clinical information, radiological data, serum, peripheral blood lymphocytes, plasma, cerebrospinal fluid (CSF), DNA and tissue specimens collected prospectively from participants with cancer and autoimmune diseases.

The purpose of this study is to determine whether intravenous immunoglobulin (IVIG) treatment reduces significantly the number of epileptic seizures in cases of autoimmune epileptic seizures.

The purpose of this study is to define the molecular defects leading to the breakdown of self-tolerance in Rheumatoid Arthritis (RA) and compare them to immune abnormalities in other autoimmune diseases.
 

The purpose of this study is to determine the prevalence, diagnostic accuracy and predictors of antinueronal antibody positivity in serum and cerebrospinal fluid (CSF) of patients iwth focal epilepsy of unknown cause (high) compared to patients with epilepsy of known cause (intermediate) and idiopathic genetic generallized epilepsy (low).  

This research study is being done to find out whether autoimmune mechanisms are associated with the development of atrial fibrillation.

Recently, Interleukin (IL)-17 has been identified as a key driver of chronic inflammation in Bullous Pemphigoid (BP). Ixekizumab is a recombinant high-affinity fully human monoclonal antibody that targets IL-17A Immunoglobulin gamma-1 (IgG1)/kappa-class. The purpose of this study is to determine the effect of Ixekizumab on BP patients.

The purpose of this study is to create a research registry of patients with Immune-Mediated Inflammatory Skin Conditions (IMISC) within academic and community, real-world practices in order to assess the safety and effectiveness of current and future therapies.

The overall objective of this proposal is to conduct a systematic approach to dissect both genetic underpinnings and non-genetic factors in the development of adult autoimmune liver diseases including autoimmune hepatitis (AIH), overlap AIH with Primary Biliary Cirrhosis (AIH-PBC), overlap AIH with Primary Sclerosing Cholangitis (AIH-PSC), and drug-induced autoimmune-like hepatitis (DIAIH).

We plan to create a databank of serum and tissue samples from patients with thyroid autoimmunity, mainly focusing on Graves’ disease and Graves’ orbitopathy, respectively. This set of samples will allow us to study these disorders better in the laboratory as well as test potential agents that can be used as therapies.

The purposes of this study are to explore the therapeutic efficacy of BAFFR-CAR T cells in BAFFR-expressing B-cell hematologic malignancies including large B-cell, mantle cell and follicular lymphoma, chronic lymphocytic leukemia (CLL) and B-cell acute lymphoblastic leukemia (B-cell ALL) using primary tumor and/or patient derived xenograft models, and to explore the therapeutic efficacy of BAFFR-CAR T cells in autoimmune rheumatologic diseases including  systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis using primary samples and/or patient derived xenograft models.